FDA Gives Plasma Thumbs Up for U.S. COVID Treatment

The U.S. Food and Drug Administration (FDA) has given emergency use authorization for doctors to treat COVID-19 patients with blood plasma from recovered COVID-19 patients. According to the FDA, trial evidence suggests that plasma helps hospitalized COVID-19 patients when given within 3 days after hospitalization.

President Trump has called out the FDA on Twitter for delaying drug treatments and vaccine approvals, going so far as to suggest the agency would delay treatment approvals until after the election for political reasons. FDA Director Stephen Hahn said the agency’s decision was made independent of any interactions with President Trump.

According to the FDA, approval was granted because the agency found plasma use to be safe in a trial of 20,000 COVID-19 patients. The survival rate in trial patients was increased by 35% within a month after receiving the treatment. Patients under age 80 and not on a respirator are considered most likely to benefit from getting blood plasma.

About 70,000 patients have received plasma so far.

Disclaimer: This article does not provide medical advice. Do not take action based solely on this article and always consult with an appropriate healthcare professional. This article is purely for informational purposes.

Add Comment